Prognostic Impact of Six Versus Eight Cycles of Standard Regimen in Patients With Diffuse Large B-Cell Lymphoma

2020 ◽  
Author(s):  
Kana Oiwa ◽  
Kei Fujita ◽  
Shin Lee ◽  
Tetsuji Morishita ◽  
Hikaru Tsukasaki ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Prognostic Impact ◽  
Standard Regimen ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals New agents and regimens for diffuse large B cell lymphoma

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Liang Wang ◽  
Lin-rong Li ◽  
Ken H. Young
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Checkpoint Inhibitors ◽  
B Cell Lymphoma ◽  
Classification Systems ◽  
Genetic Classification ◽  
Standard Regimen ◽  
Treatment Approaches ◽  
Large B Cell Lymphoma ◽  
Large B Cell

AbstractAs a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHOP and fare poorly. Unsatisfied outcomes for those relapsed/refractory patients prompted efforts to discover new treatment approaches for DLBCL, including chimeric antigen receptor T cells, bispecific T cell engagers, immunomodulatory drugs, immune checkpoint inhibitors, monoclonal antibodies, antibody–drug conjugates, molecular pathway inhibitors, and epigenetic-modifying drugs. Herein, up-to-date data about the most promising treatment approaches for DLBCL are recapitulated, and novel genetic classification systems are introduced to guide individualized treatment for DLBCL.

scholarly journals Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients

2010 ◽  
Vol 23 (5) ◽  
pp. 686-693 ◽  
Author(s):  
Sari Riihijärvi ◽  
Satu Koivula ◽  
Heidi Nyman ◽  
Karin Rydström ◽  
Mats Jerkeman ◽  
...  
Keyword(s):  
Protein Kinase C ◽  
Protein Kinase ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Prognostic Impact ◽  
Kinase C ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era

2009 ◽  
Vol 100 (10) ◽  
pp. 1842-1847 ◽  
Author(s):  
Ritsuko Seki ◽  
Koichi Ohshima ◽  
Tomoaki Fujisaki ◽  
Naokuni Uike ◽  
Fumio Kawano ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Prognostic Impact ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma

2019 ◽  
Vol 41 (1) ◽  
pp. 50-56
Author(s):  
Laura Fogliatto ◽  
Kamila Castro Grokoski ◽  
Yuri Machado Strey ◽  
Tito Vanelli ◽  
Christina Garcia da Silva Fraga ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Prognostic Impact ◽  
Proliferative Index ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document